Implications of Obesity for Drug Therapy: Limitations and Challenges

被引：149

作者：

Jain, R. ^{[1
,2
]}

Chung, S. M. ^{[1
,2
]}

Jain, L. ^{[1
,2
]}

Khurana, M. ^{[1
,2
]}

Lau, S. W. J. ^{[1
,2
]}

Lee, J. E. ^{[1
,2
]}

Vaidyanathan, J. ^{[1
,2
]}

Zadezensky, I. ^{[1
,2
]}

Choe, S. ^{[1
,2
]}

Sahajwalla, C. G. ^{[1
,2
]}

机构：

[1] US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol, Silver Spring, MD 20993 USA

[2] US FDA, Ctr Drug Evaluat & Res, Off Translat Sci, Silver Spring, MD USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 90卷 / 01期

关键词：

ORAL-CONTRACEPTIVE USE; LEAN BODY-WEIGHT; VENOUS THROMBOSIS; PHARMACOKINETICS; DISPOSITION; CYP2E1; RISK; PHARMACODYNAMICS; DESCRIPTOR; MORTALITY;

D O I：

10.1038/clpt.2011.104

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Obesity has become a worldwide challenge with significant health and socioeconomic implications. One of the major implications is its impact on drug therapy. In order to gain a better understanding of this impact, we surveyed the regulatory guidances, the newly approved molecular entity drug products, and drug product labels in the Physician's Desk Reference. This review summarizes the findings of the survey along with the existing knowledge on pharmacokinetic and pharmacodynamic changes associated with obesity.

引用

页码：77 / 89

页数：13

共 83 条

[1] Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use [J].